Atopic dermatitis. Atopic dermatitis, unspecified
Conditions
Interventions
Intervention 1: Control group: In this group, patients receive topical betamethasone and an emollient twice a day. They have also prescribed a placebo tablet (which looks similar to melatonin) at bedt
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age between 18-65 years Satisfaction to participate in the study
Exclusion criteria
Exclusion criteria: Extent of involvement less than 2% or more than 30% of the body surface Skin problems other than atopic dermatitis Severe systemic diseases (kidney disease, diabetes, uncontrolled hypertension, and other chronic diseases) Use of systemic medications for atopic dermatitis 4 weeks before the start of the study Use of topical medications for atopic dermatitis 2 weeks before the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scaling severity. Timepoint: 4, 8 and 12 weeks and 3 months after intervention. Method of measurement: Scoring Index for Atopic Dermatitis (SCORAD).;Blister severity. Timepoint: 4, 8 and 12 weeks and 3 months after intervention. Method of measurement: Scoring Index for Atopic Dermatitis (SCORAD).;Redness severity. Timepoint: 4, 8 and 12 weeks and 3 months after intervention. Method of measurement: Scoring Index for Atopic Dermatitis (SCORAD).;Dermatitis severity. Timepoint: 4, 8 and 12 weeks and 3 months after intervention. Method of measurement: Scoring Index for Atopic Dermatitis (SCORAD). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFariba Iraji
Esfahan University of Medical Sciences
Outcome results
None listed